Semax Peptide Protects Liver Function in Rats Under Acute and Chronic Stress
Background
Stress, whether acute or chronic, can significantly impact various physiological systems, including the liver. The liver plays a crucial role in metabolism and detoxification, and prolonged stress can lead to oxidative stress and hepatocyte dysfunction. ACTH4-7-PGP, commonly known as Semax, is a synthetic peptide derived from adrenocorticotropic hormone (ACTH) known for its neuroprotective and adaptogenic properties. This study aimed to investigate if Semax could mitigate stress-induced lipid peroxidation and functional changes in hepatocytes in a rat model.
Results
In rats subjected to acute foot-shock stress, Semax demonstrated a dose-dependent effect on lipid peroxidation. Specifically, doses of 50 μg/kg and 450 μg/kg normalized the elevated malondialdehyde (MDA) levels in liver homogenate, indicating a reduction in oxidative damage. Conversely, lower doses of 5 μg/kg and 150 μg/kg significantly increased MDA content, suggesting a pro-oxidant effect at these specific concentrations without essential changes in antioxidant defense activity. Importantly, Semax at all tested doses (5, 50, 150, and 450 μg/kg) consistently decreased the stress-induced elevation of serum aspartate aminotransferase (AST) activity, a key marker of liver cell damage. In the chronic stress model, Semax provided substantial benefits, leading to the normalization of protein synthetic hepatocyte function and serum alanine aminotransferase (ALT) activity, another crucial indicator of liver health. This protective effect on protein synthesis and ALT was observed with less pronounced impact on lipid peroxidation in chronic conditions. The most significant finding was Semax's ability to normalize key markers of liver damage and function, including aspartate aminotransferase (AST) activity across all doses in acute stress, and alanine aminotransferase (ALT) activity and protein synthetic function in chronic stress.
Why It Matters
This study provides compelling evidence for the hepatoprotective potential of Semax in mitigating stress-induced liver damage and dysfunction. The peptide's ability to normalize liver enzyme activities and protein synthesis under both acute and chronic stress conditions highlights its therapeutic promise. Given that chronic stress is a pervasive issue with significant health consequences, including liver pathology, these findings suggest Semax could be a valuable agent for supporting liver health. Further research, including human clinical trials, is warranted to explore Semax's efficacy as a therapeutic intervention for stress-related liver disorders. Future studies should also investigate the underlying mechanisms of its biphasic effect on lipid peroxidation.